Become a Member

Track your favourite stocks
Create & monitor portfolios
Daily portfolio value

Company	Chg	Chg %
Quickpicks
£	%
Add shares to your quickpicks to display them here!

Nuformix (NFX) Share News

Nuformix interim loss virtually flat as continues work on drugs

13th Dec 2022 14:54

(Alliance News) - Nuformix PLC on Tuesday reported a negligibly smaller half-year loss as it continued to work on treatments for cancer and fibrosis, a disease which scars tissues in the lungs. Read More

TRADING UPDATES: Neometals swings to loss; Funding Circle strikes deal

23rd Sep 2022 21:02

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Friday and not separately reported by Alliance News: Read More

UK shareholder meetings calendar - next 7 days

18th Aug 2022 16:01

IN BRIEF: Nuformix shares rise on tolerability studies completion

10th Aug 2022 11:14

Nuformix PLC - London-based pharmaceutical firm targeting fibrosis and oncology - Says NXP002, a potential treatment for idiopathic pulmonary fibrosis, has successfully completed pre-clinical tolerability studies. "Tolerability has been demonstrated across a new range of doses, including higher doses than previously given," it explains. Work now commences to explore how the new doses studied can best optimise efficacy and the treatment's positive pharmacological profile. Read More

EXECUTIVE CHANGES: Cohort co-founder out; Nuformix co-founder back

28th Jul 2022 16:14

(Alliance News) - The following is a round-up of London-listed company director and manager changes announced on Thursday and not separately reported by Alliance News: Read More

EARNINGS UPDATES: Alliance Trust beats benchmark and ups dividend

28th Jul 2022 15:01

(Alliance News) - The following is a round-up of earnings by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More

IN BRIEF: Nuformix shares rise as progresses with cancer programme

29th Jun 2022 12:25

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Starts to scale-up the production processes of lead cocrystals for its cancer programme NXP004, focused on the treatment for advanced ovarian cancer. Firm aims to develop new forms of Olaparib, "currently marketed by AstraZeneca PLC, under the Lynparza brand name," Nuformix explains. First approved in 2014 for advanced ovarian cancer, it has since received "similar approvals in breast, pancreatic and prostate cancers with further trials on-going." Read More

TRADING UPDATES: Anglo-Eastern Plantations sees palm oil prices rise

27th Jun 2022 21:51

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More

Nuformix Executive Chair Alastair Riddell resigns after one year

31st May 2022 12:41

(Alliance News) - Nuformix PLC on Tuesday said Executive Chair Alastair Riddell has resigned with immediate effect. Read More

IN BRIEF: Nuformix shares plunge on inconsistent repeat study results

30th May 2022 11:54

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Says the contract research organisation undertaking the final planned pre-clinical study for its NXP002 treatment had a protocol failure, which has voided the study. Says the organisation repeated the study and recorded results that were inconsistent with the first in vivo study at all time points and also with the oral control. Notes that no positive or negative conclusions could be drawn from this study. Read More

SMALL-CAP WINNERS & LOSERS: Foxtons finds new CEO; S4 revenue surges

30th May 2022 11:13

(Alliance News) - The following stocks are the leading risers and fallers among London Main Market small-caps on Monday. Read More

IN BRIEF: Nuformix NXP004 patent application reaches publication phase

28th Mar 2022 19:18

Nuformix PLC - London-based pharmaceutical development firm focused on fibrosis and oncology via drug repurposing - Says patent application for key asset NXP004 had progressed to the publication phase. NXP004 is a new formulation of Olaparib, which is used to treat ovarian, breast and pancreatic cancers currently marketed by FTSE 100-listed AstraZeneca PLC, under the name Lynparza. The patent application, which was made in September 2020, covers new olaparib oxalic acid cocrystals, their therapeutic uses and pharmaceutical compositions containing them. A second patent application was filed last November which remains pending. Read More

FTSE 100 Latest

Value8,837.91

Change26.87